BRCA2 oncogenic variants

About

Gene context: BRCA2

Biomarker Type: Somatic Variant

Present: True

Chromosome: 13

Requires Oncogenic: True


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
FDA (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone
EMA (1) FDA (2) HSE (2) BRCA2 oncogenic variants Ovarian Epithelial Tumor Olaparib
EMA (1) FDA (2) HSE (2) BRCA2 oncogenic variants High-Grade Serous Fallopian Tube Cancer Olaparib
EMA (1) FDA (2) HSE (2) BRCA2 oncogenic variants Peritoneal Serous Carcinoma Olaparib
EMA (1) FDA (1) HSE (1) BRCA2 oncogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1) BRCA2 oncogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
EMA (1) FDA (1) BRCA2 oncogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone
FDA (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone
FDA (1) BRCA2 oncogenic variants Ovarian Epithelial Tumor Rucaparib
FDA (1) BRCA2 oncogenic variants High-Grade Serous Fallopian Tube Cancer Rucaparib
FDA (1) BRCA2 oncogenic variants Peritoneal Serous Carcinoma Rucaparib
FDA (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Rucaparib
FDA (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
EMA (1) HSE (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisolone